



## **Accugenix Announces Next Generation Sample Submission Process for Microbial Identifications**

**Perfection of sample extractions from FTA<sup>®</sup> ELUTE Micro Cards  
eliminates need for subculture or shipping of bacteria and fungi**

Newark, DE – July 25, 2007 – Accugenix, Inc. announces the development of a new sample submission process that allows microbial DNA extractions from Whatman's FTA<sup>®</sup> ELUTE Micro Cards. Organizations seeking genetic-based microbial identification services are now able to follow a simple procedure to inactivate microbes and store their DNA on the paper cards for safer shipping. This process eliminates the need for subculturing or shipping media plates. FTA Elute Micro Cards utilize patented Whatman FTA Technology, which allow an unknown organism's DNA to be sent in an envelope for identification services, significantly lowering costs and simplifying handling. Upon receipt at Accugenix, the DNA stored on the card is extracted for amplification and use in the company's microbial identification processes.

"Our perfection of this technique for extracting bacterial and fungal DNA from FTA cards improves both the simplicity and robustness of the sample submission process for companies using our microbial identification services," according to Mike Waddington, Vice President of Operations at Accugenix. "This new capability dramatically reduces the handling and shipping costs of providing samples for identification, and stabilizes an unknown organism's DNA to reduce variations that can occur in cultures during shipping."

FTA Elute Cards are manufactured and distributed by the Whatman Group. The technology enables scientists to collect, transport, archive, and isolate DNA and RNA samples at room temperature in a single step. "FTA Cards rapidly inactivate organisms, including blood-borne pathogens, and prevent the growth of bacteria and other microorganisms," says Dr Walter King, VP of R&D at Whatman. "Accugenix's ability to extract DNA for microbial identification purposes further demonstrates the exceptional utility of our FTA technology and its ability to immobilize and stabilize genomic samples for downstream purification and use."

\* \* \* \* \*

**About Accugenix:**

Accugenix, a privately held company based in Newark, DE, is a market leader in genetic-based microbial identification services for customers in the Pharmaceutical, Biotechnology and Medical Device product industries. The company's core competencies in specialized testing methods, data analysis and interpretation have resulted in the identification of hundreds of thousands of organisms by comparative DNA sequencing – more than any other service laboratory in the industry. Further information can be obtained at the company's website, [www.accugenix.com](http://www.accugenix.com).

**About Whatman:**

A global leader in separations technology, Whatman provides innovative life science products and solutions for the scientific community. Whatman has developed total sample preparation solutions to improve research in a wide range of fields. Our robust line of filtration devices and membranes enables us to provide novel solutions for the laboratory, environmental, pharmaceutical, and food and beverage markets. For more information, visit us at [www.whatman.com](http://www.whatman.com).